Clinical trial
Phase 2 Study of Afatinib Plus Toripalimab in Previously Treated Recurrent or Metastasic Esophageal Squamous Cell Carcinoma With EGFR Overexpression or EGFR Amplification
NCT04880811 is registered in ClinicalTrials.gov with Peking University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study of Afatinib Plus Toripalimab in Previously Treated Recurrent or Metastasic Esophageal Squamous Cell Carcinoma With EGFR Overexpression or EGFR Amplification
- Lead sponsor
- Peking University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 31, 2021
- Completion date
- May 31, 2023
- Enrollment
- 43 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.